Adam R. Renslo

Adam R. Renslo

Auto-generated profile, based on publicly available information

Adam R. Renslo

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2013 in eLife
Verified
Journal Article
Open access
CSCarmela Sidrauski
Carmela Sidrauski
DADiego Acosta-Alvear
Diego Acosta-Alvear
AKArkady Khoutorsky
Arkady Khoutorsky
PVPunitha Vedantham
Punitha Vedantham
BHBrian R Hearn
Brian R Hearn
PWPeter Walter
Peter Walter
Phosphorylation of the α-subunit of initiation factor 2 (eIF2) controls protein synthesis by a conserved mechanism. In metazoa, distinct stress conditions activate different eIF2α kinases (PERK, PKR, GCN2, and HRI) that converge on phosphorylating a unique serine in eIF2α. This collection of signaling pathways is termed the ‘integrated stress response’ (ISR). eIF2α phosphorylation diminishes protein synthesis, while allowing preferential translation of some mRNAs. Starting with a cell-based screen for inhibitors of PERK signaling, we identified a small molecule, named ISRIB, that potently (IC50 = 5 nM) reverses the effects of eIF2α phosphorylation. ISRIB reduces the viability of cells subjected to PERK-activation by chronic endoplasmic reticulum stress. eIF2α phosphorylation is implicated in memory consolidation. Remarkably, ISRIB-treated mice display significant enhancement in spatial and fear-associated learning. Thus, memory consolidation is inherently limited by the ISR, and ISRIB releases this brake. As such, ISRIB promises to contribute to our understanding and treatment of cognitive disorders.

1 July 2013 in Cell
Verified
Journal Article
Closed access
PFPu Fan
Pu Fan
DMDevanand S. Manoli
Devanand S. Manoli
OAOsama M. Ahmed
Osama M. Ahmed
YCYi Chen
Yi Chen
NANeha Agarwal
Neha Agarwal
NSNirao M. Shah
Nirao M. Shah

1 December 2006 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ARAdam R Renslo
Adam R Renslo
JMJames H McKerrow
James H McKerrow

14 July 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MAMaha-Hamadien Abdulla
Maha-Hamadien Abdulla
DRDebbie S. Ruelas
Debbie S. Ruelas
BWBrian Wolff
Brian Wolff
JSJune Snedecor
June Snedecor
KLKee-Chong Lim
Kee-Chong Lim
CCConor R. Caffrey
Conor R. Caffrey
Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied on phenotypic (whole organism) screening with adult worms in vitro and/or animal models of disease—tools that limit automation and throughput with modern microtiter plate-formatted compound libraries. A partially automated, three-component phenotypic screen workflow is presented that utilizes at its apex the schistosomular stage of the parasite adapted to a 96-well plate format with a throughput of 640 compounds per month. Hits that arise are subsequently screened in vitro against adult parasites and finally for efficacy in a murine model of disease. Two GO/NO GO criteria filters in the workflow prioritize hit compounds for tests in the animal disease model in accordance with a target drug profile that demands short-course oral therapy. The screen workflow was inaugurated with 2,160 chemically diverse natural and synthetic compounds, of which 821 are drugs already approved for human use. This affords a unique starting point to ‘reposition’ (re-profile) drugs as anti-schistosomals with potential savings in development timelines and costs. Multiple and dynamic phenotypes could be categorized for schistosomula and adults in vitro, and a diverse set of ‘hit’ drugs and chemistries were identified, including anti-schistosomals, anthelmintics, antibiotics, and neuromodulators. Of those hits prioritized for tests in the animal disease model, a number of leads were identified, one of which compares reasonably well with PZQ in significantly decreasing worm and egg burdens, and disease-associated pathology. Data arising from the three components of the screen are posted online as a community resource. To accelerate the identification of novel anti-schistosomals, we have developed a partially automated screen workflow that interfaces schistosomula with microtiter plate-formatted compound libraries. The workflow has identified various compounds and drugs as hits in vitro and leads, with the prescribed oral efficacy, in vivo. Efforts to improve throughput, automation, and rigor of the screening workflow are ongoing. The flatworm disease schistosomiasis infects over 200 million people with just one drug (praziquantel) available—a concern should drug resistance develop. Present drug discovery approaches for schistosomiasis are slow and not conducive to automation in a high-throughput format. Therefore, we designed a three-component screen workflow that positions the larval (schistosomulum) stage of S. mansoni at its apex followed by screens of adults in culture and, finally, efficacy tests in infected mice. Schistosomula are small enough and available in sufficient numbers to interface with automated liquid handling systems and prosecute thousands of compounds in short time frames. We inaugurated the workflow with a 2,160 compound library that includes known drugs in order to cost effectively ‘re-position’ drugs as new therapies for schistosomiasis and/or identify compounds that could be modified to that end. We identify a variety of ‘hit’ compounds (antibiotics, psychoactives, antiparasitics, etc.) that produce behavioral responses (phenotypes) in schistosomula and adults. Tests in infected mice of the most promising hits identified a number of ‘leads,’ one of which compares reasonably well with praziquantel in killing worms, decreasing egg production by the parasite, and ameliorating disease pathology. Efforts continue to more fully automate the workflow. All screen data are posted online as a drug discovery resource.

30 March 2018 in Science
Verified
Journal Article
Closed access
PDF file
JTJordan C. Tsai
Jordan C. Tsai
LMLakshmi E. Miller-Vedam
Lakshmi E. Miller-Vedam
AAAditya A. Anand
Aditya A. Anand
PJPriyadarshini Jaishankar
Priyadarshini Jaishankar
HNHenry C. Nguyen
Henry C. Nguyen
PWPeter Walter
Peter Walter
ISRIB mechanism of action: In rodents, a druglike small molecule named ISRIB enhances cognition and reverses cognitive deficits after traumatic brain injury. ISRIB activates a protein complex called eIF2B that is required for the synthesis of new proteins. Tsai et al. report the visualization of eIF2B bound to ISRIB at near-atomic resolution by cryo–electron microscopy. Biochemical studies revealed that ISRIB is a “molecular staple” that promotes assembly of the fully active form of eIF2B. Zyryanova et al. report similar structures together with information on the binding of ISRIB analogs and their effects on protein translation. Science , this issue p. eaaq0939 , p. 1533

15 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DBDavid B. Berry
David B. Berry
DLDuo Lu
Duo Lu
MGMichal Geva
Michal Geva
JWJoel C. Watts
Joel C. Watts
SBSumita Bhardwaj
Sumita Bhardwaj
KGKurt Giles
Kurt Giles
Significance: As people live longer, the prevalence and economic impact of neurodegenerative diseases rise. No cures or effective treatments exist for any of these fatal disorders, so identifying potential therapeutics that extend survival in animal models is vital. Many neurodegenerative illnesses have been shown to be caused by the accumulation of self-propagating misfolded proteins—the hallmark of prion diseases. We report the efficacy of 2-aminothiazoles, which were identified in cell-based screens as antiprion compounds, in extending the lives of prion-infected animals. Efficacy was limited by the development of drug-resistant prions, which is likely to have important implications for creating therapeutics in many different neurodegenerative diseases.